MAs attenuate LPS-induced inflammatory responses by activating the Nrf2 pathway, which in turn inhibits the ROS/NLRP3/IL-1β signaling axis. This mechanism suggests potential therapeutic applications of MAs in managing inflammation-related diseases. The gene discussed is NLRP3; the disease is inflammation.